Work Here?
Overview
Sirtex provides liver-directed cancer treatment using SIR-Spheres Y-90 resin microspheres delivered through the hepatic artery to irradiate liver tumors from within. The tiny beads lodge in tumor vessels and emit radiation, killing cancer cells while minimizing exposure to healthy tissue. This catheter-based internal radiation therapy (SIRT) is distinct from external beam radiation or systemic drugs, with a history of regulatory approvals in the US and Europe and a shift from public to private ownership. The goal is to offer effective, targeted radiotherapy for inoperable liver tumors and expand access to SIRT globally, maintaining leadership in this specialized field.
About Sirtex
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Acquired
Total Funding
$30K
Headquarters
Sydney, Australia
Founded
1997
Get referred to Sirtex
See people who can refer or advise you
Simplify's Take
What believers are saying
- FLEXdose SELECT in 2024 improved dosing flexibility and broadened physician adoption.
- January 2026 Magle extension adds embolization products and US market expansion leverage.
- DOORwaY90’s 99% ORR gives Sirtex strong launch evidence for HCC conversions.
What critics are saying
- Revenue still leans heavily on SIR-Spheres; one clinical setback would hit the franchise.
- DOORwaY90’s HCC bet depends on reimbursement adoption against entrenched hospital workflows by 2027.
- CDH and China Grand control Sirtex; geopolitical friction can constrain capital and strategy.
What makes Sirtex unique
- SIR-Spheres remains a differentiated, FDA-cleared Y-90 resin platform for liver tumors.
- DOORwaY90 on April 13, 2026 showed 100% local tumor control in HCC.
- Europe MDR certification in 2024 and SIROS launch expanded its delivery moat.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$30k
Above
Industry Average
Funded Over
3 Rounds
Benefits
Flexible Work Hours
Hybrid Work Options
Health Insurance
Paid Sick Leave
Paid Vacation
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%Sirtex Medical, a company known for developing treatments for liver cancer, has received EU certification for its SIR-Spheres Y-90 resin microspheres and launched its new SIROS Delivery System in Europe.
Sirtex announces SIR-Spheres® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plansWOBURN, Mass., Aug. 5, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the launch of its SIR-Spheres® FLEXdose SELECT Delivery Program, an innovative, new way to offer precise Y-90 selective internal radiation therapy for the treatment of metastatic colorectal cancer.SIR-Spheres® FLEXdose SELECT Delivery Program offers unparalleled flexibility by enabling tailored, patient-specific dosing from a single 3mL delivery vial. This program also marks the availability of 3mL SIR-Spheres® vials, which contain a reduced volume of microspheres (approximately 27 million compared to 44 million in the current 5mL vials). With up to five days pre-calibration available every day of the week, the novel Y-90 delivery program offers a vial of SIR-Spheres® designed for more selective treatment targeting."We're pleased to introduce this latest innovation in Y-90 radioembolization therapy to treat a broader spectrum of tumor burden," said Matt Schmidt, CEO of Sirtex Medical Limited. "The SIR-Spheres® FLEXdose SELECT Delivery Program reflects our continued focus on listening to the needs of patients and physicians by enabling access to personalized Y-90 resin doses and expedited patient treatments.""I have found the SIR-Spheres® FLEXdose Program to be extremely helpful in treating my patients on a timely basis," explained Ripal Ghandi, M.D., a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute and the course director for the Symposium on Clinical Interventional Oncology. "With this program, I can personalize the Y-90 treatment for each of my patients using a product that is available every day of the week
Sirtex Medical appoints Matt Schmidt as new chief executive officer and board of directors member.
Mr. Smith joins Inogen from Sirtex Medical Limited, a previously ASX-listed leading manufacturer of interventional treatment solutions, where he most recently served as Chief Executive Officer since 2019.
Sirtex unveils first-of-its-kind product to treat peripheral vascular hemorrhageWOBURN, Mass., Oct. 27, 2023 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.LAVA® provides volume and viscosity options that optimize the flexibility needed to treat patients with controlled target vessel occlusion. The product's 2mL and 6mL options are optimized for the peripheral vasculature, and its viscosity options allow for the distal embolization of small vessels that may be inaccessible via other embolics."This product's ability to maximize the packing density within the target vessel is incredibly important, as it allows us to minimize the likelihood of a future recurrence or restoration of vessel patency," said Dr. Gary Siskin, Professor and Chairman of the Department of Radiology at Albany Medical Center.In a study of the LAVA® Liquid Embolic System for the embolic treatment of arterial hemorrhage in peripheral vasculature, the product met both the primary safety and effectiveness endpoints, with 100% of patients experiencing no major adverse events in 30 days and 94% of lesions meeting clinical success in 30 days."The trial was an incredible success. Our goal was to achieve 70% efficacy for the existing data and outcomes, but we were able to achieve 94% efficacy," said Dr. Bulent Arslan, Professor of the Division of Interventional Radiology and Director of Vascular and Interventional Radiology at RUSH Medical College
Sirtex is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Sirtex
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
Acquired
Total Funding
$30K
Headquarters
Sydney, Australia
Founded
1997
Sirtex is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today